|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010328
|
4-epi-11-E4t-NeuroP
|
3-((1R,2R,3R)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010143
|
4-epi-4-D4c-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2S,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010146
|
4-epi-4-D4t-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2R,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010271
|
4-epi-4-E4c-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2S,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010274
|
4-epi-4-E4t-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2R,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010161
|
7,10-diepi-7-D4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2S,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010160
|
7,10-diepi-7-D4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2R,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010289
|
7,10-diepi-7-E4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2S,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010288
|
7,10-diepi-7-E4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2R,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010229
|
7,14-diepi-14-D4c-NeuroP
|
(Z)-6-((1S,2S,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010228
|
7,14-diepi-14-D4t-NeuroP
|
(Z)-6-((1R,2R,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010357
|
7,14-diepi-14-E4c-NeuroP
|
(Z)-6-((1S,2S,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010356
|
7,14-diepi-14-E4t-NeuroP
|
(Z)-6-((1R,2R,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010167
|
7-D4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2S,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010170
|
7-D4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2R,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010295
|
7-E4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2S,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010298
|
7-E4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2R,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010233
|
7-epi-14-D4c-NeuroP
|
(Z)-6-((1S,2S,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010232
|
7-epi-14-D4t-NeuroP
|
(Z)-6-((1R,2R,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010361
|
7-epi-14-E4c-NeuroP
|
(Z)-6-((1S,2S,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010360
|
7-epi-14-E4t-NeuroP
|
(Z)-6-((1R,2R,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010153
|
7-epi-4-D4c-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2S,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010152
|
7-epi-4-D4t-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2R,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010281
|
7-epi-4-E4c-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2S,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010280
|
7-epi-4-E4t-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2R,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010159
|
7-epi-7-D4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2S,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010162
|
7-epi-7-D4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2R,5S)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010287
|
7-epi-7-E4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2S,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010290
|
7-epi-7-E4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2R,3R)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010180
|
ent-10,13-diepi-10-D4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010181
|
ent-10,13-diepi-10-D4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010308
|
ent-10,13-diepi-10-E4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2R,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010309
|
ent-10,13-diepi10-10-E4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2S,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010240
|
ent-10,17-diepi-17-D4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010241
|
ent-10,17-diepi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010368
|
ent-10,17-diepi-17-E4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,3S)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010369
|
ent-10,17-diepi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,3S)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010174
|
ent-10-D4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010171
|
ent-10-D4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010302
|
ent-10-E4c-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010299
|
ent-10-E4t-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010182
|
ent-10-epi-10-D4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010179
|
ent-10-epi-10-D4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,5R)-5-hydroxy-3-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010310
|
ent-10-epi-10-E4c-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,2R,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010307
|
ent-10-epi-10-E4t-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,2S,3S)-3-hydroxy-5-oxo-2-((Z)-pent-2-en-1-yl)cyclopentyl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010236
|
ent-10-epi-17-D4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,5R)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010237
|
ent-10-epi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,5R)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010364
|
ent-10-epi-17-E4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,3S)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010365
|
ent-10-epi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,3S)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010156
|
ent-10-epi-7-D4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2R,5R)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|